Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monoclonal antibody therapy for cancer has evolved significantly over decades.
• Early approaches faced challenges with nonspecific targeting and low drug potency.
• Key parameters like antigen selection, linker stability, and drug efficacy are crucial for effective antibody-drug conjugates (ADCs).

Purpose of the Study:

• To provide an overview of the research and development leading to Brentuximab vedotin.
• To highlight the critical parameters addressed in the development of effective ADCs.

Main Methods:

• Review of historical and contemporary studies in ADC development.
• Analysis of critical parameters influencing ADC efficacy and safety.

Main Results:

• Brentuximab vedotin emerged as a highly active ADC, incorporating solutions to previously identified challenges.
• The development process refined antigen and tumor target selection, linker technology, and drug conjugation methods.

Conclusions:

• Successful ADC development requires meticulous attention to multiple critical parameters.
• Brentuximab vedotin's success validates the importance of addressing these factors in cancer therapy.